Background. Leiomyosarcoma is a soft tissue sarcoma whose outcome has historically been confounded by the inclusion of gastrointestinal stromal tumors. Thus, we sought to determine the factors that predict survival and recurrence in patients with primary leiomyosarcoma alone. Methods. During 1982-2006, a total of 353 patients with primary resectable leiomyosarcoma were identified from a prospective database. Multivariate analysis was used to assess clinicopathologic factors for association with disease-specific survival (DSS). Competing risk survival analysis was used to determine factors predictive for local and distant recurrence. Results. Of 353 patients, 170 (48 %) presented with extremity, 144 (41 %) with abdominal/retroperitoneal, and 39 (11 %) with truncal tumors. Median age was 57 (range, 18-88) years, and median follow-up was 50 (range, 1-270) months. Most tumors were high grade (75 %), deep (73 %), and completely resected (97 %); median size was 6.0 (range, 0.3-45) cm. Abdominal/retroperitoneal location was associated with worse long-term DSS compared to extremity or trunk (P = 0.005). However, by multivariate analysis, only high grade and size were significant independent predictors of DSS. Overall, 139 patients (39 %) had recurrence: 51 % of those with abdominal/retroperitoneal, 33 % of extremity, and 26 % of truncal disease. Significant independent predictors for local recurrence were size and margin, whereas predictors for distant recurrence were size and grade. Site was not an independent predictor of recurrence; however, late recurrence ([5 years) occurred in 9 % of abdominal/ retroperitoneal and 4 % of extremity lesions. Conclusions. Grade and size are significant independent predictors of DSS and distant recurrence. Long-term follow-up in leiomyosarcoma is important, as late recurrence continues in 6-9 % patients.
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Leiomyosarcoma is a common form of soft tissue sarcoma that is composed of cells showing distinct smooth muscle features. 1 The term leiomyosarcoma encompasses a spectrum of disease ranging from low-grade cutaneous lesions with relatively benign behavior to aggressive deep lesions of the abdomen or extremity with significant metastatic potential. [1] [2] [3] The natural history of gastrointestinal leiomyosarcoma has been confounded with gastrointestinal stromal tumor (GIST) because these tumors have similar gross and microscopic appearance. [4] [5] [6] Most of the so-called smooth muscle tumors arising in the gastrointestinal tract, mesentery, and omentum are GISTs, defined by the presence of activating mutations in KIT or PDGFRA and expression of CD117 and/or CD34. Leiomyosarcoma, characteristically positive for smooth muscle actin and desmin, forms a significant percentage of retroperitoneal and pelvic sarcomas and is the predominant sarcoma arising from large blood vessels. 1 Thus, with the advent of molecular pathology, a better definition of GISTs, and more frequent use of immunohistochemical stains, distinguishing leiomyosarcoma histologically has become more accurate.
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There is a paucity of literature that defines the outcomes for primary leiomyosarcoma patients alone. An article on nonvisceral leiomyosarcomas investigated clinical characteristics associated with outcome. 8 Although the authors found that grade, depth, and size correlated with metastasisfree survival, they did not report outcome in patients with primary disease alone and did not define sites of recurrence. Furthermore, because abdominal lesions were excluded, there were no outcome data for this site. Similarly, in a previous study from our institution, the majority of leiomyosarcoma patients (63 %) presented with metastasis and/ or local recurrence. 9 This study also included patients with uterine leiomyosarcoma, a biologically different disease.
The goal of our study was to report the natural history of primary leiomyosarcoma-specifically, how the site of the primary tumor relates to outcome as determined by disease-specific survival (DSS). Secondarily, we sought to determine the common sites of failure and the clinicopathologic features that are predictive of local recurrence (LR) and distant recurrence (DR).
METHODS
Between July 1, 1982, and June 30, 2006, a total of 7,066 adult patients admitted and treated at Memorial Sloan-Kettering Cancer Center were identified from a prospective soft tissue sarcoma database after we received institutional review board approval. The diagnosis of leiomyosarcoma was defined by characteristic pathologic features on hematoxylin and eosin staining consisting of ovoid or cigar-shaped nuclei with a blunt end, variably eosinophilic cytoplasm, and uniform positive staining for a-smooth muscle actin, desmin, and/or h-caldesmon, whereas all GISTs (CD117 ? and CD34 ? ) were excluded. 1 All patient pathology that included the diagnosis of leiomyosarcoma or GIST in the database from 1982 to 2000 had been previously rereviewed by Christina Antonescu as part of previous GIST studies, and thus all the patient tumors included in this study had the immunohistochemical support to characterize them as leiomyosarcoma. Tumors in a uterine site were excluded because they are a distinct biologic entity. 2 Patients were excluded with metastases or LR at presentation (n = 247), or if disease was deemed unresectable at the time of surgery (n = 32). Thus, the study cohort consisted of 353 patients with primary leiomyosarcoma who presented for surgical resection.
Clinicopathologic data included age at presentation, gender, depth, grade, size, site, and margin status. Anatomic depth was evaluated relative to the investing superficial fascia. Tumor grade was classified as high or low on the basis of the degree of cellularity, degree of differentiation, number of mitoses per 10 high-powered fields, and amount of tumor necrosis. 10 Tumor size was recorded as the largest dimension of the primary tumor and also stratified as B5 cm,[5 cm to 10 cm, or [10 cm. Margins of resected specimen were defined as R0 (negative), R1 (microscopically positive), or R2 (grossly positive). Sites of disease were defined as: (1) extremity-upper and lower extremity, (2) abdominal/retroperitoneal-any lesion in the abdomen or retroperitoneum, and (3) trunk-chest wall, groin, and thoracic. The primary end point of the analysis was DSS, defined as time from date of initial presentation to date of death as a result of disease or complication. The influence of clinicopathologic features on DSS was analyzed by the competing risk survival analysis method, and the effect of each prognostic factor was examined by Gray's test. Finally, a competing risk analysis was performed to determine predictive factors for LR and DR.
Survival analysis was performed by the R software and the cmprsk package. A P value of \0.05 was considered significant.
RESULTS

Patient and Tumor Characteristics
The study included 353 patients (Table 1 ) with a median age of 57 (range, 18-88) years. The extremity was the most common site (n = 170), followed by abdominal/retroperitoneal sites (n = 144), whereas truncal lesions (n = 39) represented 11 % of the group. The majority of primary leiomyosarcomas were high grade (75 %) and deep (73 %). Nevertheless, we were able to obtain complete (R0 ? R1) resection in 97 % of patients (Table 1) , although the percentage varied by site (not shown).
DSS Analysis
At a median follow-up of 50 (range, 1-270) months, 172 patients were alive. On univariate analysis, the known prognostic markers of grade, size, depth, and primary site were significant variables ( Table 2 ). The 5-year DSS by site was 75, 81, and 67 % for extremity, truncal, and abdominal/retroperitoneal groups, respectively (Supplementary Fig. 1 ; P = 0.005, Table 2 ). Strikingly, we found no disease-related deaths in the extremity or truncal groups after approximately 8 years; in the abdominal/retroperitoneal group, patients continued to die of their disease over the long term ( Supplementary Fig. 1 ).
Multivariate analysis was performed by a competing risk analysis to identify prognostic factors that are important for DSS ( Table 2 
Features of Leiomyosarcoma Recurrence by Site
A recurrence occurred in 139 of the 353 patients (39 %). The rate of first recurrence varied by site: 51 % of abdominal/retroperitoneal, 33 % of extremity, and 26 % of truncal patients. Among the 139 patients with recurrence, the pattern of initial recurrence was predominately DR, which occurred in 93 patients (67 %), whereas 30 patients (22 %) had a LR and 16 patients (11 %) had both LR and DR (Fig. 1a) . First recurrences that were LR only were substantially higher for abdominal/retroperitoneal than for truncal and extremity patients (30 vs. 20 % and 11 %). In contrast, distant-only first recurrences were 82 % for extremity patients, 80 % for truncal patients, and 53 % for abdominal/retroperitoneal patients (Fig. 1a) .
The most common site of metastasis as either the site of first recurrence or subsequent disease dissemination was DSS disease-specific survival, CI confidence interval a Size not available for 4 patients lung, followed by liver and soft tissue (Fig. 1b) . Less frequent sites of metastasis included bone, soft tissue metastasis in the chest wall exclusive of lung parenchyma, and abdomen or retroperitoneum. Although lung was the most common site of DR, the frequency of soft tissue, bone, and hepatic involvement varied substantially by site of primary lesion. Metastasis to bone occurred in 9 % of extremity patients and 10 % of abdominal/retroperitoneal patients, whereas no truncal patients developed bony metastasis. Similarly, hepatic metastasis occurred in 23 % of abdominal/retroperitoneal patients and 8 % of extremity patients, but was not observed in truncal patients (Fig. 1c) .
The rates of DR and LR varied by primary leiomyosarcoma site (Fig. 2) . LR rates at both 5 and 10 years were 10 % for extremity and 11 % for truncal patients, with no local failures for either primary site after 5 years (Fig. 2a) . In contrast, abdominal/retroperitoneal patients had a much higher LR rate at 5 years (21 %), which continued to rise to 27 % at 10 years. The 5-year DR rates were 43, 32, and 31 % for the abdominal/retroperitoneal, extremity, and truncal patients, respectively. Truncal patients did not have any DR beyond 5 years, whereas late DR (5-10 years after diagnosis) occurred in 6 % of extremity patients and in 9 % of abdominal/retroperitoneal patients (Fig. 2b) . ii. iii.
ii. 
Factors Predictive of LR and DR
We performed a competing risk analysis for both LR and DR (Table 3) . Prognostic factors for LR were size [10 cm (HR 2.9, 95 % CI 1.2-6.7) and margin status R1 versus R0 (HR 2.1, 95 % CI 1.1-3.9), as we excluded R2 margins in our analysis. For DR, the prognostic factors were grade (HR 3.9, 95 % CI 1.9-7.8) and size (HR 2.6, 95 % CI 1.5-4.6).
DISCUSSION
In this study, we present a natural history study of primary leiomyosarcoma ranging over 25 years. To our knowledge, this is the largest series of its kind that excludes GIST and uterine site, as these two tumor types are separate biologic diseases. Before the advent of molecular pathology, published studies fail to discriminate between leiomyosarcoma of the gastrointestinal tract and GIST. 5, 6 Estimates of the true incidence of leiomyosarcoma range from 2 to 10 % of all smooth muscle sarcomas of the gastrointestinal tract.
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Predictive Factors for DSS in Leiomyosarcoma
The most important independent predictors for DSS in patients with primary leiomyosarcoma are grade (HR 3.7 for high vs. low) and size (HR 3.4 for[10 vs.\5 cm; HR 1.8 for 5-10 vs.\5 cm). Although site was a significant univariate predictor of DSS and we found a higher frequency of late leiomyosarcoma-specific deaths to be associated with the abdominal/retroperitoneal site, site was not an important predictor of DSS after adjusting for grade and size. The fact that 27 % of abdominal/retroperitoneal leiomyosarcoma patient and 7 % of extremity and truncal patients will die of disease more than 5 years after diagnosis supports the need for follow-up beyond 5 years, particularly for patients with abdominal/retroperitoneal tumors.
Our survival data cannot easily be compared with those from previous studies because those studies included patients with metastases, unresectable disease, LR, uterine disease, or GISTs, or they excluded abdominal and/or retroperitoneal sites. 5, 6, 8, 9, [15] [16] [17] Nevertheless, grade has also been found to be a predictor of leiomyosarcoma-specific CI confidence interval a R2 margins were excluded survival in other series. 8, 9, 16, 17 However, in contrast to previous reports, we did not find margin status predictive. 9, 17 This is likely explained by different R0 resection rates: 55 and 48 % compared to 82 % in our series.
9,17 Also, we did not find age to be a predictive factor for DSS, unlike previous studies. 15, 17 In one series, elderly patients had a much higher incidence of metastasis during follow-up (67 vs. 25 % for those above vs. below age 62); however, the reasons for this observation are unclear. 17 Furthermore, we did not find a higher incidence of female patients than male patients (Table 1) . 9 Finally, mitotic index was not examined in our study; although it can be useful in discriminating leiomyomas from leiomyosarcoma and in determining grade, its use as an independent prognostic factor has not been validated in larger leiomyosarcoma series. 2, 3, 16, 17 Patterns of Leiomyosarcoma Recurrence: Sites of Failure and Predictive Factors for Local and Distant Disease
To our knowledge, this study represents the first comprehensive analysis of the timing and sites of recurrence according to site of primary disease (Fig. 1) . Collectively, our recurrence data define which leiomyosarcoma sites are prone to DR and LR, and when and where these events are likely to occur.
The cumulative incidence of recurrence varied significantly by site (Fig. 1) . Extremity and truncal patients had approximately a 10 % cumulative incidence of LR, all of which occurred within 5 years of resection (Fig. 2a) . This is consistent with a previous study of similar primary sites in which an 8 % LR rate was observed, and all recurrences occurred within 2 years of resection. 17 Abdominal/retroperitoneal patients in our study had a higher incidence of LR (21 % at 5 years), as well as a substantial incidence of LR (Fig. 2a) . With respect to DR, we were surprised to find that 6 % of extremity and 9 % of abdominal/retroperitoneal patients developed DR more than 5 years from primary tumor diagnosis (Fig. 2b) , emphasizing the need for longterm follow-up in both the retroperitoneal and extremity subgroups.
Lung was the most common site of metastasis, regardless of the site of the primary tumor (Fig. 1b, i) , a finding that has been previously reported. 1, 9, 17 The second most common site of metastasis was other soft tissue sites in extremity patients (15 % of all DR) and liver in abdominal/ retroperitoneal patients (23 % of all DR). In contrast, primary truncal leiomyosarcomas did not metastasize to liver, bone, or nonlung thoracic sites, yet the second most common site of metastasis in truncal patients was abdominal/ retroperitoneal soft tissue (30 % of all DR).
In our competing risk survival analysis, size and margin status are important prognostic factors for LR, whereas size and grade are prognostic for distal recurrence. In a recent Scandinavian study that did not include abdominal and/or retroperitoneal leiomyosarcoma, decreased metastasis-free survival was similarly associated with grade, size, and depth. 8 This study, however, did not define clinicopathologic features associated with LR except for inadequate local treatment, which was defined as marginal tumor resection or an intralesional surgical margin with or without radiotherapy. 8 Thus, our study is the first to define the clinical characteristics associated with LR for the most common sites of leiomyosarcoma.
Patients with low-grade, superficial, or small (\5 cm) leiomyosarcomas (n = 43) had more favorable outcomes, as the 5-year DSS was 98.5, 90, and 91 %, respectively ( Table 2 ). None of the 5 truncal patients in this subgroup experienced recurrence. However, of the 38 ''favorable'' extremity patients, 1 patient developed a LR at 3 years, followed by distant disease at 5 years, but currently has no evidence of disease; and another patient died of disease after the development of distant disease 6 years after diagnosis.
Although our study did not examine survival after metastasectomy in leiomyosarcoma patients, we have found reasonable median survival in patients with complete resection of liver metastasis, especially when recurrence develops more than 2 years after diagnosis. 18 We observed significant late disease-specific mortality in patients with abdominal and/or retroperitoneal disease, as approximately 6 % die of disease after 8 years. Such late disease-specific mortality has not been previously reported, presumably because of smaller patient series or shorter follow-up. 9, 19 These abdominal/retroperitoneal patients also continue to experience LR and DR even 10 years or more from the diagnosis of primary disease (Fig. 2) . Therefore, we strongly recommend that sarcoma centers continue surveillance for recurrence for the lifetime of these patients.
Conclusions
Grade and size are the most important prognostic factors for DSS and DR in patients with primary leiomyosarcoma. Site is not an important independent prognostic factor for LR in this series; however, size and margin are. Long-term follow-up of leiomyosarcoma patients is important because late LR or DR occurs in 9 % of abdominal/retroperitoneal patients and 6 % of extremity patients.
